23596-25-0

Basic information

• Product Name: 6-Chloro-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine
• Synonyms: 6-Chloro-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine;1H-Pyrrolo[3,2-c]pyridine, 6-chloro-2,3-dihydro-
• CAS NO: 23596-25-0
• Molecular Formula: C7H7ClN2
• Molecular Weight: 154.6
• Mol File: 23596-25-0.mol
• Article Data: 8

Chemical Properties

• Melting Point: 115-116 °C
• Boiling Point: 287.2°Cat760mmHg
• Flash Point: 127.5°C
• Appearance: /
• Density: 1.291g/cm³
• Vapor Pressure: 0.00253mmHg at 25°C
• Refractive Index: 1.585
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 4.31±0.20(Predicted)
• CAS DataBase Reference: 6-Chloro-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine(23596-25-0)
• EPA Substance Registry System: 6-Chloro-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine(23596-25-0)

Safety Data

• Hazardous Substances Data: 23596-25-0(Hazardous Substances Data)

Usage

General Description

6-Chloro-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine, also known as LY379268, is a chemical compound with potential pharmaceutical applications. It is a selective agonist for the metabotropic glutamate receptors, particularly subtype 2 and 3 (mGlu2/3). 6-Chloro-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine has been studied for its potential use in treating a variety of central nervous system disorders, including schizophrenia, anxiety, and depression. It has also shown promise as an anti-inflammatory agent and has been investigated for its potential role in treating neurodegenerative diseases. Its ability to modulate glutamate levels in the brain makes it a promising candidate for the development of novel pharmaceuticals for these and other neurological conditions.

InChI:InChI=1/C7H7ClN2/c8-7-3-6-5(4-10-7)1-2-9-6/h3-4,9H,1-2H2

Upstream product

• 800402-12-4 2-chloro-4-amino-5-iodopyridine 
• 14432-12-3 4-Amino-2-chloropyridine 
• 74976-31-1 6-chloro-1H-pyrrolo[3,2-c]pyridine 
• 66751-33-5 6-hydroxy-5-azaindoline 
• 68-12-2 N,N-dimethyl-formamide 
• 66751-32-4 1-benzyl-6-chloro-7-cyano-5-azaindoline 

Downstream Products

• 1649470-12-1 tert-butyl 6-chloro-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 80862-08-4 6-methoxy-5-azaindole 
• 74976-33-3 3-(4-methyl-1-piperazinylmethyl)-6-chloro-5-azaindole 
• 74976-31-1 6-chloro-1H-pyrrolo[3,2-c]pyridine 
• 24603-30-3 6-methoxy-5-azaindoline 

Relevant articles and documents

RORγ MODULATORS

The invention provides an RORγ receptor agonist comprising a compound of formula (I), wherein the variables are as defined herein. These compounds are analogous to known RORγ receptor antagonists. The invention further provides a method of activating -the nuclear receptor RORγ, comprising -contacting the RORγ with an effective amount or concentration of a compound of the invention; and a method of treating cancer in a patient, comprising administering to the patient an effective dose of a compound of the invention.

Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP

(Figure Presented) Inhibitor of apoptosis proteins (IAPs) are important regulators of apoptosis and pro-survival signaling pathways whose deregulation is often associated with tumor genesis and tumor growth. IAPs have been proposed as targets for anticanc

PPAR ACTIVE COMPOUNDS

Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.